Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation
DOI:
https://doi.org/10.19156/cbn.2016.0008Keywords:
BRCA, recurrent ovarian cancer, trabectedinAbstract
Treatment of patients with recurrent ovarian cancer (ROC) is complex. This case report describes the effects of a sequence of treatments in a BRCA1 mutation carrier with serous papillary poorly differentiated, platinumsensitive ROC. This consisted in primary surgery, adjuvant chemotherapy, secondary cytoreduction with Heated IntraPEritoneal Chemotherapy (HIPEC), 12 cycles of trabectedin in combination with pegylated liposomal doxorubicin (PLD) and 12 cycles of trabectedin alone, leading to complete radiological and biochemical response.Downloads
Published
2016-03-15
How to Cite
1.
Greco F, Piacentini P, Remo A, Bonetti A, Ferrandina G. Case 2 – Trabectedin as a maintenance therapy in a patient with recurrent ovarian cancer and BRCA1 germline mutation: . CBN [Internet]. 2016 Mar. 15 [cited 2024 Nov. 23];4(1):41-4. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/204
Issue
Section
Meet the expert
License
Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.